Therapy of Hypoparathyroidism by Replacement with Parathyroid Hormone
Figure 4
Changes in areal bone mineral density (aBMD) and volumetric bone mineral density (vBMD) as assessed by DXA and QCT scans, respectively. Changes were assessed between baseline and 24 weeks of trial during which studied patients were treated with 100 μg of (read) or placebo (blue) [20].
